Millions will be able to sign up for ‘life-changing' clinical trials through the NHS app
The move is part of Streeting's Ten-Year Health Plan
APP BOOST Millions will be able to sign up for 'life-changing' clinical trials through the NHS app
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
MILLIONS will be able to sign up for 'life-changing' clinical trials through the NHS app.
Health Secretary Wes Streeting has vowed to speed up access to ground-breaking treatments by making medical research studies available to join via smartphone.
Sign up for Scottish Sun
newsletter
Sign up
2
Health Secretary Wes Streeting is making medical research studies available to join via smartphone
Credit: Getty
The move could slash trial set-up times from 250 days to 150 or fewer by next year.
Patients will receive push notifications from the app matching them to relevant studies based on their health data.
NHS Trusts will be ranked on trial performance.
Funding will be prioritised for the best.
The moves are part of Mr Streeting's Ten-Year Health Plan, due shortly.
He said: 'The app will become the digital front door to the NHS.
"It will enable us to play our part in developing the medicines of the future.'
Wes Streeting brutally slams Kemi AND Farage and demands Tories say sorry for how they ran the NHS in blistering attack
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
25 minutes ago
- Daily Mail
Back pain can be eased with walking – but there's a specific number of minutes to reach per day
Hitting 10,000 steps a day is a goal for millions of us. But the number of minutes we walk for may be a more important target to focus on. Scientists believe being on your feet for over an hour-and-a-half every day could slash the risk of chronic lower back pain. Norwegian and Danish researchers found people who walk for over 100 minutes a day cut this risk by almost a quarter compared to those who clocked 78 minutes per day or less. They also discovered faster walkers were less likely to have chronic back pain—but the effect was less pronounced than walking for longer. Experts, who labelled the findings important, urged policy makers to push walking as a 'public health strategy' to reduce the risk of the agonising condition. In many cases, lower back pain starts suddenly and improves within a few days or weeks. But if it sticks around for more than three months, it's classed as chronic, according to the NHS. In some cases, it can be considered a disability. In the study, 11,194 Norwegians, with an average age of 55, were quizzed on their health and how much exercise they did per week. Almost a sixth (14.8 per cent) reported suffering from lower back pain, answering 'yes' to the following questions, 'During the last year, have you had pain and/or stiffness in your muscles or joints that lasted for at least three consecutive months? and 'Where have you had this pain or stiffness?' Participants were considered to have the condition if they answered yes to the first question and reported pain in the lower back to the second. Both men and women were involved in the study, and 100 minutes was found to be the optimum length of time for both sexes, and all ages. Writing in the journal JAMA Network Open, the researchers concluded: 'Compared with walking less than 78 minutes per day, those who walked more than 100 minutes per day had a 23 per cent reduced risk of chronic lower back pain. 'The reduction in risk of chronic lower back pain leveled off beyond a walking volume of about 100 minutes per day. 'Our findings suggest that daily walking volume is more important than mean walking intensity in reducing the risk of chronic lower back pain. 'These findings suggest that policies and public health strategies promoting walking could help to reduce the occurrence of chronic lower back pain.' The researchers also noted that their results are 'likely generalisable beyond the Norwegian adult population, as physical inactivity prevalence in Norway is comparable to that observed in other high-income countries'. They did note some limitations of the study, including that participants with higher walking volume tended to exercise more often and reported higher physical work demands, which might give them a physical advantage over other members of the group. In the UK, musculoskeletal conditions (MSK)—including back pain—are the second biggest reason for people being 'economically inactive'—where someone is out of work and not looking for work. Figures released by the Government in December 2024 revealed that MSK conditions affect approximately 646,000 Britons, 1-in-4 of the 2.8m who are claiming long-term sickness benefits. MSK comes second only to mental health issues for reasons why people are unable to work. It was estimated that 23.4 million working days in the UK were lost due to MSK conditions in 2022. NHS waiting lists for MSK community services are the highest of all community waits in England, with 348,799 people in September 2024 waiting to see a specialist. As part of their Get Britain Working White Paper, the Government pledged a £3.5million package to 17 Integrated Care Boards (ICBs) across England to improve local MSK services.
Scottish Sun
an hour ago
- Scottish Sun
Cereal lovers have just three minutes to finish their breakfast before sogginess kicks in, research reveals
Some Brits say that a soggy breakfast can ruin their morning, as Kellogg's announces a new sog-defying cereal CEREAL KILLER Cereal lovers have just three minutes to finish their breakfast before sogginess kicks in, research reveals CEREAL lovers have a three-minute window to finish their bowl – before sogginess ruins the most important meal of the day. While almost half report tucking into a bowl of cereal most mornings, 32 per cent admit to panicking about it going limp in too much milk, rising to 45 per cent in London, a poll of 2,000 adults shows. 2 The challenge of getting the cereal just soggy enough is so serious some report getting it wrong can ruin their whole morning Credit: Getty 2 Kellogg's are releasing a brand new sog-defying cereal to help Brits keep that all important crunch Credit: Getty The research reveals that for 15 per cent, starting the day with a soggy bowl is enough to ruin their whole morning. That said, some actually prefer it that way – with a similar number claiming they like their cereal fully soaked, while half insist it must keep its crunch. Of these, 55 per cent reckon it makes for a better eating experience, and 53 per cent say it simply pairs better with milk Many reported that opting for a cereal breakfast makes for a smoother morning with their children. Seven in 10 said it is quick to prepare and eases the process of getting kids ready in the morning, and half admitted it's a meal their kids will actually eat. The research was commissioned by Kellogg's to mark the launch of Oaties – a new oat based cereal. Food scientists have developed the cereal over the last 18 months and created what is believed to be the first sog-defying cereal, thanks to its unique shape and high fibre ingredients. The study also delved into Brits' breakfast habits, revealing a strong loyalty to dairy – with 91 per cent opting for cow's milk with their cereal. When it comes to milk substitutes, oat milk has been tried by 38 per cent, while 33 per cent have poured on almond milk. And 18 per cent have even thought about using hot chocolate. Gwyneth Paltrow puts on a very cheeky display as she cooks topless and serves up a 'boyfriend breakfast Cereal toppers are getting more adventurous too, as 13 per cent have considered adding ice cream, 10 per may add avocado, and eight per cent have flirted with toppings like cheese or even a hard-boiled egg. Regular toppings are still most popular though, with 33 per cent adding fresh fruit, 23 per cent going for a drizzle of honey and 21 per cent mixing in yoghurt. While seven per cent have been mixing in protein powder to kickstart the day.
Daily Mail
2 hours ago
- Daily Mail
NHS 'faces hike in drugs prices' as part of government's trade deal with Trump as US president seeks to help Big Pharma
The NHS could see billions added to its annual drugs bill under the trade deal done by Keir Starmer with Donald Trump 's America. The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad. The health service in England currently uses a drug-pricing scheme that sees drug-makers discount the price of medicine sold in bulk to avoid it busting a £20billion cap. But manufacturers have claimed the system is not viable and risks investment in the UK because it is more expensive than the schemes used by other countries. They pay back almost a quarter of their UK sales to the Government in rebates to avoid busting the cap, far more than the 15 per cent estimated and way above the average 5.7 per cent rebate in France, 7 per cent in Germany and 9 per cent in Ireland. The deal done at the start of May promised the sector 'significantly preferential treatment', with ministers vowing 'to improve the overall environment for pharmaceutical companies operating in the UK'. A White House source told the Telegraph it expected the NHS to start paying more to improve the balance sheets of American firms. Last week the CEO of Pfizer accused the UK and other European nations of 'free-riding all these years' on the back of US-based investment in pharmaceuticals. Albert Bourla told a conference that given US pressure on European countries to pay more, prices there could increase. He suggested the Trump administration should treat the sector like Nato defence spending and demand US allies pay more of their GDP into it. The US is also demanding the UK use fewer cheaper drugs from China, the Telegraph claimed. The President threatened to slap a 25 per cent tariff on UK pharmaceuticals entering the US, which last year totalled £6.6 billion. He also issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. Health Secretary Wes Streeting is reviewing the rebate, which is likely to be wrapped in with ongoing US tariff talks, sources add. The UK spends a smaller share of its overall healthcare costs on medicines than any comparable country, according to the Association of the British Pharmaceutical Industry (ABPI), whose members includeUS drugs giants such as Pfizer, Bristol Myers Squibb, Amgen, Johnson & Johnson, Merck and Biogen.
